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Abstract
Healthcare systems are currently adapt-
ing to digital technologies, producing
large quantities of novel data. Based on
these data, machine-learning algorithms
have been developed to support practi-
tioners in labor-intensive workflows such
as diagnosis, prognosis, triage or treat-
ment of disease. However, their transla-
tion into medical practice is often ham-
pered by a lack of careful evaluation in
different settings. Efforts have started
worldwide to establish guidelines for
evaluating machine learning for health
(ML4H) tools, highlighting the neces-
sity to evaluate models for bias, inter-
pretability, robustness, and possible fail-
ure modes. However, testing and adopt-
ing these guidelines in practice remains
an open challenge. In this work, we tar-
get the paper-to-practice gap by apply-
ing an ML4H audit framework proposed
by the ITU/WHO Focus Group on Arti-
ficial Intelligence for Health (FG-AI4H)
to three use cases: diagnostic prediction
of diabetic retinopathy, diagnostic pre-
diction of Alzheimer’s disease, and cyto-
morphologic classification for leukemia
diagnostics. The assessment comprises
dimensions such as bias, interpretability,
and robustness. Our results highlight
the importance of fine-grained and case-
adapted quality assessment, provide sup-
port for incorporating proposed quality
assessment considerations of ML4H dur-
ing the entire development life cycle, and
suggest improvements for future ML4H
reference evaluation frameworks.
Keywords: Machine Learning, Health,
Testing
Healthcare systems generate large amounts
of data from medical imaging, sensors, or
electronic health records. Modern machine
learning technology has been developed to
analyze big data for health, promising to
reduce cost and labor for diagnostics and
prognostics in different medical fields (Topol,
2019; Esteva et al., 2019). A sprawling
ecosystem comprising academic, corporate,
and institutional capital has produced nu-
merous machine learning for health (ML4H)
use cases such as detecting diabetic retinopa-
thy in retina images (Gulshan et al., 2016)
or predicting Alzheimer’s disease from MRI
images (Moradi et al., 2015). The ex-
ploratory excitement is matched by demands
for a rigorous assessment of efficacy and
safety as is standard protocol for any tech-
nological innovation in healthcare. Thus,
a colorful smorgasbord of initiatives such
as STARD-AI (Sounderajah et al., 2020),
CONSORT-AI (Liu et al., 2020), SPIRIT-AI
(Liu et al., 2020) and the World Health Orga-
nization (WHO)/International Telecommuni-
cation Union (ITU) Focus Group on Artificial
Intelligence for Health (FG-AI4H) (Wiegand
et al., 2019) created guidelines for transpar-
ent assessment of ML4H performance. In-
tegrating these guidelines into the machine
learning (ML) development process to meet
technical, ethical, and clinical requirements
is challenging. While there appears to be no
shortage in good practice guidelines on pa-
per, the question on how well they can be
adopted in practice remains unanswered. In
this paper, we report findings of applying
the ITU/WHO FG-AI4H assessment guide-
lines to three ML4H use cases: 1) diagnostic
prediction of Diabetic Retinopathy (DR), 2)
diagnostic prediction of Alzheimer’s disease
(Alzheimer’s Disease (AD)) and 3) cytomor-
phologic cell classification to aid leukemia di-
agnostics. We find that the protocol helps to
uncover model weaknesses while also posing
challenges during its application. We com-
ment on these challenges and provide sugges-
tions for further research directions in this
field.
1. Related work and contributions
The aspiration towards reliable and safe
ML4H products has led to multiple initia-
tives that provide guidance for quality assur-
ance. Next to the initiatives mentioned in
the introduction, these include the FDA (US-
© 2020 L. Oala et al.
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FDA, 2019), International Medical Device
Regulators Forum (IMDRF) (IMDRF, 2019),
academic voices like He et al. (2019) and
others summarized in (Wenzel and Wiegand,
2020). In addition, the academic ML commu-
nity proposed standardized reporting for data
resources (Gebru et al., 2018) and model de-
velopment (Mitchell et al., 2019; Sendak et al.,
2020; Raji et al., 2020). Furthermore, special-
ized software packages have emerged, often
focusing on either a specific quality aspect,
such as the AI Fairness 360 toolkit (Bellamy
et al., 2018), a particular step in the ML life
cycle, such as robust model training (Nicolae
et al., 2018) or benchmarking Papernot et al.
(2018); Hendrycks and Dietterich (2019).
However, to the best of our knowledge no
work exists on applying a ML4H quality as-
sessment guideline to existing use cases. This
is what we call the paper-to-practice gap:
abstract guidelines and specialized tools are
available but they are not being applied. De-
creasing the paper-to-practice gap is the main
motivation of this work. Our team of test en-
gineers collaborated with three clinical use
case owners to carry out a trial audit follow-
ing the FG-AI4H assessment guideline. We
report implications of applying ML4H qual-
ity assessment guidelines in practice, audit
results as well as positive and negative ex-
periences with the FG-AI4H process. Our
report can help other use case owners and
stakeholders from ML4H quality assessment
initiatives to improve their work.
2. Use Cases
In a call for participation, we chose three
use cases based on the developers’ capacity
to share the model and testing data from
different input modalities, that is, imaging
and structured data. The use case models
were developed by teams in the United States,
India, Switzerland and Germany.
(1) Diagnostic prediction of diabetic
retinopathy Diabetic retinopathy is a sight-
threatening complication of diabetes in adults
(Yau et al., 2012). Retinal scanning during
routine diabetes care is crucial to detect the
onset of DR at an early stage (Namperumal-
samy et al., 2003). A company based in the
United States and India has developed a deep
neural network (DNN)-based algorithm to dif-
ferentiate normal retina fundus images from
those with DR using a Resnet-101. More
information can be found in A.1.
(2) Diagnostic prediction of
Alzheimer’s disease AD is a neurodegen-
erative disease and the most common cause
of dementia affecting millions of patients
worldwide. AD causes progressive cognitive
decline and ultimately death (Dubois
et al., 2009a). Recently the combination of
objective brain measures from MRI with
ML has shown promising results with better
diagnostic accuracy than the symptoms
based approaches (Dubois et al., 2009b).
A group of neuroscientists in Switzerland
developed Gradient Boost and Näıve Bayes
models on structured data containing Mag-
netic Resonance (MR)-extracted brain region
volumes, age and gender for the classification
of AD and cognitively normal older adults.
More information in A.2.
(3) Cytomorphologic classification
for leukemia diagnostics Morphological
examination of leukocytes is a laborious and
time-consuming process in the diagnostic rou-
tine for hematological disorders. A team
based in Germany trained a DNN-based al-
gorithm on two tasks (i) classifying single-
cell images into a 15-category morphological
scheme derived from routine diagnostics using
a ResNeXt model (Xie et al., 2017) and (ii)
answering clinically relevant binary questions
on the blast character and atypicality of a
given single-cell image (Matek et al., 2019).
More information in Appendix A.3.
3. Method
For the audit, we chose the FG-AI4H guide-
line as evaluation framework. This choice was
motivated by the following reasons. First, the
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Figure 1: A flow chart of the FG-AI4H assessment process and its reference documents.
FG-AI4H framework contains a rich documen-
tation and is targeted specifically at ML4H.
Second, the FG-AI4H reference documenta-
tion is open-source enabling any stakeholder
to use and contribute to the guideline. Fi-
nally, due to the patronage of ITU and WHO
the FG-AI4H is closely aligned with the Sus-
tainable Development Goals. As summarized
in Figure 1, the FG-AI4H process provides
reference documentation along four steps of
the assessment life cycle: data and model
transmission (step 1), data and model under-
standing (step 2), audit (step 3), and report-
ing (step 4). In this process, use case owners
and test engineers work together towards a
final report for the use case assessment. We
provide a more detailed introduction to indi-
vidual reference documents in Appendix D. In
the following, we focus on the reference docu-
mentation that featured most prominently in
the audit simulation.
Questionnaire (J-038)1. The FG-AI4H
process provides a structured questionnaire
FG-AI4H (2020b) to elicit important informa-
tion from developers about the intended use,
data, and development process of the algo-
rithms. This information is crucial to deter-
mine if the model output fits to the intended
use and if sources of bias are present. An
1. The identifier in parentheses signifies the FG-
AI4H document for easier reference
additional aim of the questionnaire is to facili-
tate communication between developers, med-
ical domain experts and test engineers. The
questionnaire is organized into seven sections,
covering different aspects of model concerns:
basic information, intended use, data used for
development, legal aspects, ethical consider-
ations, evaluation metrics, and caveats and
recommendations. The questions for these
sections were adapted from proposed report-
ing standards ’Modelcards’ by Mitchell et al.
(2019), ’Datasheets’ by Gebru et al. (2018),
and ’Model Facts’ by Sendak et al. (2020).
Each model developer completed this ques-
tionnaire.
Bias and fairness (DEL 7.3 - Sec-
tions 5.1 and 6.2)1 According to FG-AI4H
(2020a), we performed a quantitative bias
analysis on test sets with aequitas, an open-
source bias and fairness audit toolkit for
Python (Saleiro et al., 2018). Aequitas quan-
tifies bias through disparities of group metric
values compared to a reference group. For
each attribute, we selected the group with
most samples as reference. Reference groups
always have a disparity of 1. Disparities close
to 1 indicate high similarity with the refer-
ence group. Aequitas defines fairness if dis-
parities lie within the range of 0.8-1.25 and
’unfairness’ otherwise. We performed the ae-
quitas assessment on diagnostic use cases for
283
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Alzheimer’s disease and diabetic retinopathy.
We calculated the group metrics false negative
rate (FNR), false omission rate (FOR), neg-
ative predictive value (NPV), precision and
predicted prevalence (PPREV) with aequitas
and considered FNR and FOR as most rele-
vant for diagnostic tasks where false-negatives
should to be avoided. We report model per-
formances on holdout sets with accuracy, sen-
sitivity, specificity, positive predictive value
(PPV), and NPV indicating 95% confidence
intervals (CI). The analysis was not done
for the leukemia use case as there were no
available metadata to calculate metrics across
groups.
Interpretability (DEL 7.3 - Section
6.1)1 We applied a procedure recommended
in FG-AI4H (2020a); Samek et al. (2019) and
proposed in Lapuschkin et al. (2019) to ob-
tain most representative model explanations.
These can be analysed by model developers
to identify undesired behaviour or data issues
(Pfau et al., 2019). For each use case, we
generated explanations for the test set and
grouped them by type, that is their position
in the confusion matrix. The explanations
for the DR model were generated using the
Meaningful Perturbation approach (Fong and
Vedaldi, 2017). For the AD model, we gener-
ated explanations using SHAP values (Lund-
berg et al., 2020) and Anchors (Ribeiro et al.,
2018). Finally the explanations for the cyto-
morphologic classification model were gener-
ated using the Grad-CAM method (Selvaraju
et al., 2019). After obtaining model explana-
tions, we applied DBSCAN clustering (Ester
et al., 1996) to select most representative ex-
planations. Together with model owners, we
assessed if such explanations highlight any
model issues. Details about this assessment
can be found in C.3.
Robustness (DEL 7.3 - Sections 6.3
and 6.5)1 Robustness refers to the ability
of a ML model to maintain its performance
under perturbations to the input (Li, 2018).
It is important to assess if random variations
that may occur in real-world applications af-
fect the model performance. Different types
of perturbations can be tested, but select-
ing the most realistic ones depend on the
specific use case (Hendrycks and Dietterich,
2019). Following FG-AI4H (2020a), we deter-
mine for each use case the mean corruption
error (mCE ) defined in Hendrycks and Di-
etterich (2019) and report the variation of
the probability scores due to several pertur-
bation methods. Furthermore, we document
the changes in approximated output score
densities as a proxy for a model’s sensitivity
to the noise perturbations. Details on the
robustness assessment can be found in C.4.
Reporting (J-048)1 Regular exchange
between the use case owners and test engi-
neers facilitated the auditing process, giving
test engineers the opportunity to obtain ad-
ditional information for a particular use case,
and providing use case owners feedback on
potential model weaknesses. Finally, the re-
sults from the audit process are documented
in a harmonized reporting template FG-AI4H
(2020c) that is adapted from existing good
practices (Gebru et al., 2018; Mitchell et al.,
2019; Sendak et al., 2020). The template in-
tegrates information from the questionnaire,
technical analysis, and interviews. It provides
a common interface for the communication
between use case owners and other stakehold-
ers.
4. Experiments
Each use case went through the entire au-
dit. This produced a rich repository of re-
sults and documentation. In the following,
we present highlights, selected on the premise
of exposing model weaknesses as well as in-
sightful feedback from exchanges with the
use case owners. Additional results are con-
tained in Appendix B and Appendix C. All
results are collected in a report card like Fig-
ure 5. The complete outputs from the audit
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Figure 2: FNR and FOR Fairness of di-
abetic retinopathy predictions across the
groups diabetes duration (diab dur), age-
groups (age cat), and gender (is male). ’Un-
fairness’ and ’Fairness’ within groups are
marked in red and green, respectively.
were anonymously uploaded to the FG-AI4H
server2 under identifier J-049.
Use case 1: Diagnostic prediction of
DR In the questionnaire, use case owners
stated that the intended use of their model
was to determine if Artificial Intelligence (AI)
is capable of detecting DR at an early stage to
assist in a primary care setting. From data re-
porting, it was unclear from which healthcare
context (i.e. hospital, routine or diabetic care)
the data was collected. Another unknown is
the true diabetes status of individuals with a
diabetes duration of zero years (representing
the majority in the test set at 63.4%) and
how many ophthalmologists labeled annota-
tions. Non-gradable images stemming from
operational errors were excluded from the test
set. The model performance was reported to
2. https://extranet.itu.int/sites/itu-t/
focusgroups/ai4h/SitePages/Home.aspx
be comparable to a clinician, however details
on the analysis are unknown. External vali-
dation was carried out but no details of the
data source were given. More information
elicited through the questionnaire is summa-
rized in B. To the model owners, we pointed
out a lack of metadata and cautioned that a
binary classification task distinguishing nor-
mal vs. DR images does not fulfill the task of
detecting DR at an early stage. We further
recommended to record the healthcare con-
text where patients presented and the types of
cameras used at each site. It is likely that im-
ages contain artifacts generated by different
cameras at different sites which can confound
model development. Overall performance can
be found in C.1. We stratified performance
metrics calculated with aequitas across dia-
betes duration in years (0, 1-10, 11-19, 20-29,
30+), age (groups: 10-19, 20-29, 30-39, 40-
49, 50-59, 60-69, 70+), and gender (male,
female). Figure 2 displays absolute FNR and
FOR values, with disparities outside the fair-
ness range marked as red and green otherwise.
All metric values and disparities can be found
in C.2. Aequitas indicated bias for all dia-
betes duration (diab dur) groups (except the
reference group of zero years of diabetes). In-
dividuals with 30+ years of diabetes were
underrepresented (n=6) and no false predic-
tions were made in this group. Unfair FNR
and FOR distributions were found for the
age groups of 70, 60-69, 40-49 and unknown,
with the highest metric values and dispar-
ity for 70+ years. This could be due to an
under-representation of individuals who are
70 years or older and requires further anal-
ysis. FNR and FOR were higher for males
than for females, however females represented
only 34.2% of the data. FNR, FOR, NPV,
precision and predicted prevalence metrics
with disparities across groups can be found in
table C.3. We recommend to apply strategies,
such as reweighting from the AI Fairness 360
toolkit, (Bellamy et al., 2018) that can help to
285
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Table 1: Robustness metrics for the Diag-
nostic prediction of diabetic retinopathy us-
ing mCE Hendrycks and Dietterich (2019)
for each corruption function applied, with a
Eclean = 0.2232. The lower the more robust









s,c − Efclean CE
f
c
Elastic transform 0.7252 0.0555 0.0765
Pixelate 1.0700 0.4003 0.3741
Brightness 1.4835 0.8137 0.5485
Motion blur 1.5337 0.8639 0.5633
Gaussian Blur 1.7860 1.1162 0.6250
Defocus blur 1.8454 1.1757 0.6371
Saturate 1.8732 1.2034 0.6425
Speckle noise 2.1427 1.4729 0.6874
Spatter 2.2464 1.5767 0.7019
JPEG compression 2.4730 1.8033 0.7292
Shot noise 2.6143 1.9445 0.7438
Contrast 2.6618 1.9921 0.7484
Gaussian Noise 2.7305 2.0608 0.7547
Impulse noise 2.8349 2.1651 0.7637
Fog 2.8996 2.2299 0.7690
Frost 2.9643 2.2946 0.7741
mitigate bias before classification. Model in-
terpretations were generated by the Meaning-
ful Perturbation approach (Fong and Vedaldi,
2017). The Retinopathy inputs have been
explained by maximizing the No Retinopa-
thy class activation. Explanation masks for
four images classified as Retinopathy is shown
in Figure C.9. These masks present a high
degree of noise, indicating that the model
does not focus on relevant image elements
such as arteries. Such degree of noise made
it difficult to obtain group explanations in
clusters highlighting different classification be-
haviours. Further investigation on this matter
was recommended to the model owner. The
results for the 15 tested perturbations with
3 different perturbation levels, using the test
dataset is displayed in Table 1. The mCE
for the tested perturbations indicates high ro-
bustness for brightness, pixelate and motion
blur transformations, and less robustness to
contrast, Gaussian and impulse noise trans-
formations which use case owners were made
aware of. More details on this analysis can
be found in C.4.
Use case 2: Diagnostic prediction of
AD In the model reporting questionnaire,
model owners stated the model’s primary in-
tended use was a clinical diagnostic predic-
tion model for neurology that outputs disease
class probabilities, leaving questions about
the exact target. The model owners trained a
binary classifier using Näıve Bayes and Gra-
dient Boosting algorithms to distinguish cog-
nitive normal (CN) individuals from cases
with AD. Models were trained on the pub-
licly available AD research data sets ’adni’
(Mueller et al., 2005), and ’edsd’ (Brueggen
et al., 2017). The owners also included data
from three European hospitals into training,
which could not be shared for assessment due
to data protection. Cognitive status labels are
based on possibly subjective clinical assess-
ment (i.e., cognitive testing and MR-imaging).
The model owners excluded 1,472 (65.3%)
entries from the total data set (n=2,254 in-
cluding only adni and edsd), because their
cognitive status was ’Mild cognitive impair-
ment’ (MCI) or ’Other.’ The exclusion of
these entries was not reported in the ques-
tionnaire. Models were trained with k -fold
cross validation without keeping a holdout
set. Gradient Boosting using brain volumes,
age, and gender as predictors was the best
performer, which we used for further evalu-
ation. In the questionnaire, authors stated
that they tested convolutional neural network
(CNN) and support vector machine models,
which was not available to us for evaluation.
We pointed out that a binary classifier dis-
tinguishing individuals between CN and AD
does not fulfil the intended use of clinically
relevant prediction models. The model own-
ers are working on including MCI classes,
however these reduce the model performance
significantly. We further requested to report
test results on protected data from the 3 Eu-
ropean hospitals. More information elicited
through the questionnaire is summarized in
B. As no holdout set was provided, we re-
trained the binary GradientBoost algorithm
(n=586, 75%) and performed the bias assess-
286
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Figure 3: Approximated density functions
of AD Gradient Boost scores under different
perturbation levels with lognormal noise.
ment on the holdout test set (n=196, 25%).
Overall performance can be found in C.1. We
calculated performance metrics across data
sets (either adni or edsd), age groups and
gender. Absolute group metric values and
disparities can be found in C.2. Unfairness
was detected among all three groups. Table
2 lists FNR and FOR values with disparities
for each group. FNR and FOR was higher for
edsd samples compared to samples from adni.
In the age group, FNR and FOR unfairness
was indicated for 50-59 year old individuals.
The age group of 50-59 years comprised only 7
individuals. In rare cases AD onset can start
early in life (Mendez, 2017) and it should be
evaluated if this type of AD can be detected
by the algorithm. In the gender group, the
FNR for males was higher than for females.
FOR between gender groups were distributed
equally. NPV, precision and predicted preva-
lence metrics across groups can be found in
table C.3
We used TreeSHAP to generate explana-
tions for the test set. Clustering selected 40
out of 196 points for human evaluation. For
each of these points, an explanation based
on Anchors was generated. All representa-
tive anchors contained either the brain fea-
ture rightententorhinalarea or leftententorhi-
Table 2: FNR and FOR of predicting
Alzheimer’s disease across the groups dataset,
age categories, and gender. Given are number
of samples (#), absolute metric values with
95% confidence intervals (CI) and respective
disparities δ. Disparities of 1.00 mark the
reference group.
Alzheimer’s Disease
# FNR (CI) FNR δ FOR (CI) FOR δ
dataset: adni 129 0.15 (0.09-0.22) 1.00 0.15 (0.08-0.21) 1.00
dataset: edsd 67 0.31 (0.20-0.42) 2.05 0.23 (0.13-0.33) 1.60
age cat: 50-59 7 0.50 (0.13-0.87) 2.33 0.4 (0.04-0.76) 2.71
age cat: 60-69 39 0.15 (0.04-0.26) 0.70 0.15 (0.04-0.26) 1.02
age cat: 70-79 108 0.21 (0.14-0.29) 1.00 0.15 (0.08-0.21) 1.00
age cat: 80+ 42 0.20 (0.08-0.32) 0.93 0.26 (0.13-0.40) 1.78
female 99 0.18 (0.10-0.26) 1.00 0.18 (0.11-0.26) 1.00
male 97 0.24 (0.16-0.33) 1.36 0.18 (0.10-0.26) 0.97
nalarea. Age or gender features were never an-
choring conditions. We found that the SHAP
value for age in the age groups 50-59y was
pushing the prediction towards a positive pre-
diction. This might indicate an undesired lo-
cal behaviour of the decision boundary which
could be improved by introducing monotonic-
ity constraints with respect to age. More
detailed results in C.3 While the model does
not appear sensitive to perturbations of the
gender feature (Figure C.20 and Figure C.21),
the score densities shift more drastically when
noise is applied to age and brain features (Fig-
ure 3).
Use case 3: Cytomorphologic clas-
sification to aid leukemia diagnostics
The model’s primary intended use was re-
ported as a diagnostic decision aid for medical
staff examining the leukocyte morphology in
the diagnostics of Acute Myeloid Leukemia
(AML). Data collection took place at the
Laboratory of Leukemia Diagnostics at LMU
Klinikum Munich. The model has not yet
been validated on external data. There is
no indication suggesting that sensitive de-
mographic variables might influence model
performance. The developers report that
precision and sensitivity are correlated with
the number of images in this class. Further
investigations about model generalizability
are planned. This may include cases with
other haematological diagnoses, samples from
287
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Figure 4: Two representative examples from
use case 3. The columns contain Class Activa-
tion maps corresponding the predicted class
(left) and correct class (right).
other centers, or differential sample process-
ing. As published, the model can be used as
a research-purpose decision aid only. More
information from the questionnaire is summa-
rized in A.3. Bias assessment with aequitas
was not applicable to this use case, as no
metadata was available. Model interpreta-
tions could only be obtained using the Grad-
CAM method as the model architecture was
built with the older TensorFlow 1.11 version,
which is incompatible with other, more re-
cent interpretability libraries. We grouped
class activation map (CAM)s based on their
softmax layer value and found 364 represen-
tative points out of the original 18,365 test
images. Figure 4 shows two examples of mis-
classified images, and respective CAMs. Both
examples indicate that the model learned to
focus on the leukocyte’s nucleus and cyto-
plasm, while ignoring erythrocytes and other
background structures. Beyond this check,
it remains difficult to explain the relative
contribution of individual features to the clas-
sification decision in particular when high-
lighted CAM regions are distributed across
extended regions of the input. To test the
robustness of the cytomorphology classifier,
16 perturbations were applied to 73 input im-
ages. Predictions of the classifier turned out
to be robust against most perturbations (cf.
C.4), both for correct and incorrect classifica-
tions. Some perturbations increased output
confidence of misclassifications, which may
reflect the general calibration behaviour of
the network types used in the study (Guo
et al., 2017).
5. Discussion
Standardized assessment and reporting of
ML4H quality are crucial to pave the way
for translation into medical practice. First
milestones in accommodating both technical
and health considerations in a transparent
and unified evaluation procedure have been
reached by the FG-AI4H and tangential stan-
dardization efforts. It is due time to move
these efforts from paper to practice to fur-
ther improve them. We applied a selection
of ML4H quality assessment methods from
the framework suggested by the ITU/WHO
working group FG-AI4H on three use cases.
In the following, we discuss how each step
contributed to the quality assessment, how
results were perceived by model owners and
make suggestions for further improvement
and future research.
Questionnaire: The model developers
reported that filling out the questionnaire
required between 0.5-2 hours, but helped
to review the development process critically
considering weaknesses and further improve-
ments. Transparent reporting through the
questionnaire can help to perform further
qualitative bias assessment with tools such as
PROBAST (Wolff et al., 2019).
Bias and fairness: ML4H algorithms are
prone to bias for multiple reasons. Due to
an under-representation of certain patient
groups, early disease stages or rare disease
types in healthcare data, an algorithm could
not provide the same benefit for everyone
(Gianfrancesco et al., 2018). These potential
sources of bias are included in ML4H qual-
ity assessment frameworks, but challenges
remain as data sets often do not contain vari-
288
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Figure 5: A snapshot of the FG-AI4H audit
report cards for the retinopathy use case. Full
version in Appendix B
ables that allow group stratification and test-
ing these sources. These variables are often
either not recorded or cannot be shared due
to data protection laws. More research and
policies are needed to fill this gap for bias
assessment in ML4H.
Interpretability: Interpretable model de-
cisions can help to analyse mistakes and
undesired model behaviour that can occur
from spurious correlations, for example mea-
surement artifacts, in the training data (La-
puschkin et al., 2019; Ribeiro et al., 2016;
Pfau et al., 2019). One challenge for this
assessment was that existing interpretability
analysis tools are often implemented with
external libraries that became incompatible
with model requirements. Large test data
can topple computational capacities of ex-
planation methods. Interviews with model
owners highlighted that although image in-
terpretability maps can be useful to detect
undesired behaviours, they still explain model
mistakes to a limited extent. Especially for
noisy heatmaps it is hard to identify system-
atic model mistakes. Interactive tools with
UX/UI design would be helpful to navigate
through different model behaviours.
Robustness: We assessed the robustness
of the three use cases to identify when mod-
els fail, by perturbing the input data. One
challenge with this approach is to generate
perturbations that are meaningful in med-
ical practice. Perturbations like Gaussian
noise, produce blurry images that are real-
istic through operational errors. Other per-
turbations such as frost imitations are rather
unsuitable for medical applications. It is not
yet possible to generate specific artifacts that
can be introduced during sample handling
and preparation. While artifacts, such as
morphologic changes in ageing blood sam-
ples, are well-known (Vives Corrons et al.,
2004), others may present a challenge even
to experienced examiners (Dalal and Brigden,
2002). Evaluating an algorithm on specific
artifacts hence remains challenging, for which
standard methods have yet to be established.
A limiting factor of the FG-AI4H audit
framework is that it only features a selection
of methods. We conducted analyses to cover
the quality aspects bias, interpretability, and
robustness, but did not yet perform analy-
ses on generalization. An analysis on data
quality is also recommended in the frame-
work but could not be performed on these
three use cases, as it requires raw imaging
data, which were not available. Other than
the provided clinical use case expertise, the
performed assessment does not yet address
clinical validation in itself, which requires clin-
ical studies. However, we note that limiting
the scope of ML4H auditing frameworks to
ML specific problems and exploiting estab-
lished processes for clinical assessment may
be a viable way forward to close this gap, too.
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pher K. I. Williams, and Charles Sutton.
Robust Variational Autoencoders for Out-
lier Detection and Repair of Mixed-Type
Data. arXiv, 2019. URL http://arxiv.
org/abs/1907.06671.
290
ML4H Auditing: From Paper to Practice
Martin Ester, Hans-Peter Kriegel, Joerg
Sander, and Xiaowei Xu. A density-based
algorithm for discovering clusters in large
spatial databases with noise. KDD Proceed-
ings, 1996. doi: 10.1016/B978-044452701-1.
00067-3.
Andre Esteva, Alexandre Robicquet, Bharath
Ramsundar, Volodymyr Kuleshov, Mark
DePristo, Katherine Chou, Claire Cui,
Greg Corrado, Sebastian Thrun, and Jeff
Dean. A guide to deep learning in
healthcare. Nature Medicine, 25(1):24–
29, 2019. ISSN 1546170X. doi: 10.1038/
s41591-018-0316-z. URL http://dx.doi.
org/10.1038/s41591-018-0316-z.
FG-AI4H. Data and artificial intelligence
assessment methods (daisam) reference.
Reference document DEL 7.3 on FG-AI4H
server, 2020a. URL https://extranet.
itu.int/sites/itu-t/focusgroups/
ai4h/SitePages/Home.aspx.
FG-AI4H. Model questionnaire. Reference




FG-AI4H. Daisam audit reporting template.
Reference document J-048 on FG-AI4H
server, 2020c. URL https://extranet.
itu.int/sites/itu-t/focusgroups/
ai4h/SitePages/Home.aspx.
Ruth C. Fong and Andrea Vedaldi. In-
terpretable Explanations of Black Boxes
by Meaningful Perturbation. Proceedings
of the IEEE International Conference on
Computer Vision, 2017-Octob:3449–3457,
2017. ISSN 15505499. doi: 10.1109/ICCV.
2017.371.
Timnit Gebru, Jamie Morgenstern, Briana
Vecchione, Jennifer Wortman Vaughan,
Hanna Wallach, Hal Daumeé, and Kate
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Appendix A. Detailed description of use cases
A.1. Diagnostic prediction of diabetic retinopathy
Use case description The initial goal was to develop an AI model that could be used for
screening those at risk for diabetic retinopathy in primary care settings such as doctors
offices and diabetes clinics in India for referable retinopathy.
Data The training data comprised 82,010 digital images of the retina from fundus cameras
obtained from patients being screened for diabetic retinopathy from ophthalmologists in
India. The images were in JPEG or PNG format from 2 to 5 megapixels in resolution. For
training they were resized to 224×224 pixels and normalized using ImageNet standards.
They were labeled into six categories: Nongradable, Normal, Mild, Moderate, Severe and
Proliferative DR. For binary classification Normal & Mild were grouped as ’no retinopathy’
and the rest as having retinopathy. The data is not publically available. We evaluated the
algorithm on a provided holdout test set with 848 samples of which 424 (50.0%) were cases.
The test set contained information about duration of diabetes in years, age, and gender.
The diabetes duration ranged from 0 to 40 years with a mean of 3.6 years. The majority of
individuals (n=538, 63.4%) was recorded with a diabetes duration of 0 years. Increasing
diabetes duration were represented at lower numbers (1-10y: 170, 20.0%, 11-19y: 97, 11.4%,
20-29y: 37, 4.3%, 30+y: 6, 0.7%). The age distribution ranged from 13 to 85 years, with a
median of 53. There were 38 (4.5%) entries with missing age. Men represented the majority
(n=512, 60.8%).
Architectures Initial models trained Resnet-101 Convolutional Neural Network pretrained
on ImageNet. Later models used EfficientNet-B5 architecture with pre-trained Imagenet
weights. The model which is assessed here is a Resnet-101 for binary classification of diabetic
retinopathy. Optimizers used were Adam, learning rate annealing, and FastAI’s One cycle
implementation of Cyclical learning rates. Model and data are proprietary.
A.2. Diagnostic prediction of Alzheimer’s Disease
Use case description With increased life expectancy, the number of individuals who will
potentially become demented is growing proportionally. Current estimates count world-wide
over 48 million people suffering from dementia bringing the social cost of care to 1% of
world’s gross domestic product – GDP. These numbers led the World Health Organisation
to classify neurocognitive disorders as a global public health priority. Our goal is to address
previous limitations by using “real-world” imaging data obtained in the clinical routine,
predictive ML algorithms, including benchmarking and cross-validation of the learned models.
The intended output is to assign a level of probability to each of several possible diagnosis
(Cognitively normal, MCI or AD) that is readily usable and interpretable by clinicians.
Data We used T1w brain imaging data from 2254 participants of two different multi-centric
cohorts, the ADNI (Alzheimer‘s Disease Neuroimaging Initiative) and European DTI Study
on Dementia (EDSD). From each 3D brain scan of each subject we calculated regional brain
volumes. This procedure consisted of 3 steps. 1) We segmented each brain scan into 3 tissue
classes: white matter, gray matter and CSF . 2) We spatially warped the 3D probabilistic
Neuromorphometrics atlas of each individual brain scan to get an individualised brain atlas.
3) We then calculated the volumes of each of the 134 brain regions of the atlas. The gray
matter volume is the sum of the gray matter values of the voxels of each atlas region in the
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segmented 3D image. We applied a Näıve Bayes and Gradient Boosting algorithm to the
final data that included the regional brain volumes, age and gender to distinguish cognitive
normal (CN) individuals from cases with AD.
A.3. Cytomorphologic classification to aid leukemia diagnostics
Use case description Examination of cells from the peripheral blood and bone marrow
under a light microscope is a frequently used and long-established technique in the diagnosis
of hematological disorders. For the diagnosis of leukemia in particular, morphological
examination of leukocytes retains a key role in the diagnostic routine for its comparative
technical simplicity and widespread availability. During this process, a trained examiner
classifies cells on a slide into a scheme of morphological categories. According to current
guidelines, at least 200 cells should be examined and classified in the case of bone marrow
(Döhner et al., 2017). Still today, this classification and counting of leukocytes is widely
performed manually, which is a laborious and time-consuming process and limits the
number of examinations available overall. Furthermore, manual classification is potentially
fraught with considerable intra- and inter-observer variability (P. et al., 2013). Finally, the
intrinsically subjective nature of morphological examination makes it hard to combine this
method with more recent diagnostic modalities that yield quantitative results. ML methods
such as deep learning have the potential to bridge this gap and act as a quantitatively
informed decision aid for the examiner.
Data The data comprises single-cell images from peripheral blood smears of 100 patients
diagnosed with Acute Myeloid Leukemia (AML) at LMU Klinikum Munich between 2014
and 2017, and 100 non-malignant controls. For digitization of the monolayer, an M8 digital
microscope (Precipoint GmbH, Freising/Germany) at 100x objective magnification and oil
immersion was used. A cytologist then differentiated individual leukocytes on the scanned
region in analogy with diagnostic routine. Around the annotated leukocytes, patches of
the size 400 × 400 pixels were extracted without further modification to the image data
output by the scanner. This yielded a set of 18,365 single-cell images classified into a scheme
comprising 15 morphological categories derived from routine practice. To estimate intra-
and inter-rater variability, a second, independent cytologist re-annotated the single cell
images at two different times. Details of the data generation process are described in Matek
et al. (2019). The full Munich AML Morphology Data Set is freely available on The Cancer
Imaging Archive (Matek et al.).
Architectures Models were trained on the tasks of (i) classifying a given single-cell image
into a 15-category morphological scheme derived from routine diagnostics and (ii) answering
clinically relevant binary questions on the blast character and atypicality of a given single-cell
image (Matek et al., 2019). Two distinct models were used in the training, namely the
ResNeXt model developed by Xie et al. (2017) as well as a sequential model. Hyperparameters
including the cardinality parameter were unchanged from the original setup of Xie et al.
(2017) apart from adjusting the input and output channels. Both models were trained using
the Adam optimizer. Stratified 5-fold cross-validation was used to estimate the variability of
network predictions. Details on the architecture of the sequential model are provided by
(Matek et al., 2019).
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Appendix B. Audit report in FG-AI4H template
In the following we include audit results in the FG-AI4H reporting format. In order to
avoid an indecent inflation of the appendices, the report cards for the other two use cases,
along with all other outputs of the audit process, where submitted anonymously to the




Data  Specification  Sheet  
Data  Source   Database  
Data  Acquisition/  Sensing  Modality   Fundus  camera  image  
Data  Acquisition  /  Sensing  Device  Type   Fundus  camera  
Data  Collection  Place   Chennai,  India  
Data  Collection  Period   2017—2018  
Data  Collection  Author(s)  /  Agency   Medindia4u.com  Pvt.  Ltd.  India  
Data  Collection  Funding  Agency   Medindia4u.com  Pvt.  Ltd.  India  
Data  Sampling  Rate   --  
Data  Update  Version   --  
Data  Dimension   299x299  pixel  matrix  
Data  Sample  Size   82010  images  
Data  Type   Image  (Fundus  camera)  
Data  Resolution  /  Precision   Image  Resolution:  2  to  5  Megapixels.  
Data  Privacy  /  De-identification  Protocol  
● Anonymised  datasetswere  used  
● Informed  consent:  Subjects  were  informed  about  theintended  
purpose  of  data  use   
Data  Safety  &  Security  Protocol  
● Storage  on  secure  servers  
● Used  SSL  for  all  web  access  
● Followed  best  practices  for  data  privacy  and  security  
Data  Assumptions/  
Constraints/Dependencies  
● 10  –  20%  of  images  are  non-gradable  –  ie  out-of-focus,  incorrect  
illumination,  etc  
● Input  data  include  subpopulation  variations  in  terms  of  Age:  
different,  Gender  :  M  /  F  ,  Ethnicity  :  mostly  Indian  
● input  data  was  representative  of  variations  in  data  acquisition  
modality  in  terms  ofdifferent  models  of  Fundus  Cameras   
● No  ‘missing  data’  found  for  any  predictor  variable  
Data  Exclusion  Criteria   Images  that  were  non-gradable  were  discarded  for  ML  model  
training  
Data  Acceptance-Standards  Compliance   --  
Data  Pre-processing  Technique(s)   ● A  separate  ML  model  to  identify  non-gradable  images  was  used  to  
remove  these  from  the  data  
● Images  were  resized  to  299x299  pixel  matrix  and  normalized  using  
Imagenet  mean  and  std  deviation  
Data  Annotation  Process  /  Tool   Images  are  labeled  with  the  DR  severity  levels  by  various  
ophthalmologists  
Data  Bias  &  Variance  Minimization  
Technique  
Validation  loss  was  trackedand  compared  with  training  loss  to  
ensure  bias  and  variance  were  minimized  during  training.  Techniques  
included  data  augmentation,  regularization  and  dropout.   
Train:  Tuning(validation)  :  Test  (evaluation)  
Dataset  Partitioning  Ratio  
The  total  dataset  size  of  4240  images  was  split  80%  for  training  and  
20%  for  validation  
Data  Registry  URL   Private  -  not  published  
 
 
Figure 6: The FG-AI4H data specification sheet for the retinopathy use case.
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ML  Model  Specification  Sheet  
Model  Name   Xtend.AI’s  Binary  DR  model  
Model  Version   Ver-4.0  
Model  Task   Image  classification  
Model  Target  User  Group   Ophthalmologists  
Model  Target  Patient  Group   Model  is  potentially  applicable  to  screening  of  all  population  
subgroups  
ModelAlgorithm  Type   CNN  (Resnet  101)  
Model  Output  Type   ● 2  disease  classes(  Normal&  DR)  
● Probability  of  disease  class  
Model  Evaluation  Metric(s)   ● Accuracy  
● Sensitivity  
● Specificity  
● F1  Score  
● AUROC  (Area  Under  ROC  Curve)  
Model  Optimal  PerformanceConfiguration   For  validation  data  
● Accuracy    -  0.90  
● Sensitivity   -0.90  
● Specificity   -  0.90  
● F1  Score    -0.91  
● AUROC     -  0.96  
Model  Assumptions/  
Constraints/Dependencies  
Model  optimized  for  use  in  Indian  clinical  settings  
Model  Development  Toolkit   JupyterPytorch,  Fastai  
Model  Developer   Xtend.AI  
Model  Development  Period   June  2019  –  Aug  2020  
Model  Registry  URL   Private  -  not  published  
Model  License   Proprietary  
   
 
Figure 7: The FG-AI4H model specification sheet for the retinopathy use case.
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ML  Model  Summary  Findings  
Context  Applicability   As  an  “  assistive  tool  “  for  screening  of  Diabetic  Retinopathy   
Clinical  Implications  
● Model  serves  as  a  tool  for  early  detection  of  Diabetic  
Retinopathy(  DR)  in  clinical  /  primary  care  setting  
● Model  can  be  used  to  reject  non-gradable  and  this  
reduces  sampling  errors  and  frees  the  clinician  from  
looking  at  non-gradable  images  
● Model  can  be  used  to  prioritize  the  cases  at  higher-risk  
and  refer  them  to  a  clinician  
● Model  performance  is  comparable  to  the  performance  
scores  or  the  level  of  competence  of  the  
clinician/specialist/user  in  the  clinical  setting   
Benefits    -TBD-  
Clinical  Integration  Costs   -TBD-  
Response  Time  /  Latency   -TBD-  
Efficiency  
Model  can  be  used  to  reject  non-gradable  images  –  which  
typically  represent  10  –  20%  of  the  input  dataset.  This  can  
increase  efficiency  by  reducing  sampling  errors  and  freeing  
the  clinician  from  looking  at  non-gradable  images  
Assumptions  
● For  DR  screening,  ,  ML  model  outcome  would  be  
prioritized  for  ‘  avoiding  false  negatives’  
● Relevant  subgroups  were  represented  in  the  evaluation  
dataset  
Harms   -TBD-  
Side-effects   -TBD-  
Safety  Implication   ● Stored  on  secure  servers.   ● Used  SSL  for  all  web  access  
Risks   Considered  but  unknown  
Value  proposition  /  Strengths  
● Patients  and  clinicians  were  involved  during  the  ML  
algorithm  acceptance  and  adoption  stage  
● Clinicians  were  involved  in  evaluating  ML  model  
performance  
Weaknesses/  Limitations   Model  trained  on  data  from  Indian-make  fundus  cameras  
only  
Generalisability  
Model  optimized  for  use  in  Indian  clinical  settings  and  
conforms  to  its  local  laws  and  regulations  only.  This  should  
be  taken  into  account  when  applying  the  model  elsewhere.  
User  Rating  (scale)   -TBD-  
Tradeoffs   -TBD-  
Caveats  
● As  the  ML  model  is  trained  on  data  from  Indian-make  
fundus  cameras  and  optimized  for  use  in  Indian  clinical  
settings  ,  it  may  need  to  be  retrained  if  used  for  a  different  
health  environment  
● Tool  is  intended  to  assist  in  diagnosis  and  not  as  a  
replacement  for  a  clinical  diagnosis  
Recommendations   The  ML  model  should  only  be  used  to  assist  in  detection  of  
DR  and  not  as  a  replacement  for  professional  diagnosis  




Figure 8: The FG-AI4H model summary findings sheet for the retinopathy use case.
299
ML4H Auditing: From Paper to Practice
Appendix C. Full quantitative results
C.1. Overall model performances
Diagnostic prediction of Diabetic retinopathy
The overall model performance on the test set (n=848) was 89.5% (CI: 87.4-91.6) accuracy,
89.2% (CI: 87.0-91.2) sensitivity, 89.9% (CI: 87.8-91.9) specificity, 89.8% (CI: 87.7-91.8)
PPV, and 89.2% (CI: 87.1-91.3) NPV.
Diagnostic prediction of Alzheimer’s Disease
Overall, the performance of the Gradient Boosting algorithm applied on the test set (n=196)
to predict AD or CN had 80.6% (CI: 75.1-86.1) accuracy, 79.1% (CI: 73.4-84.8) sensitivity,
81.9% (CI: 76.5-87.2) specificity, 79.1% (CI: 73.4-84.8) PPV, and 81.9% (CI: 76.5-87.3) NPV.
Cytomorphologic classification to aid leukemia diagnostics
The model developers calculated classwise precision and sensitivity performances, instead of
overall accuracy, as classes were represented at different frequencies in the data set. The
model achieved sensitivity and precision above 0.9 for classes with more than 400 samples.
Details can be found in Matek et al. (2019).
C.2. Bias and Fairness assessment with aequitas
We calculated the metric values FNR, FOR, NPV, precision, PPREV across groups. Absolute
metric values and disparities for the prediction models for Alzheimer’s disease and diabetic
retinopathy are listed in table C.3.
C.3. Interpretability assessment
C.3.1. Diagnostic prediction of diabetic retinopathy
We generated interpretability maps by applying the Meaningful Perturbation approach which
can be used to explain an input by generating a perturbation mask that minimizes the
model’s outputted probability in a constrained manner. This means generating a perturbed
version of the original input in the following form
[Φ(x0;m)](u) = m(u)x0(u) + (1−m(u))µ0. (1)
Where m is a perturbation mask used to explain the prediction, x0 is the original image
and µ0 is a perturbation background (we used a black one). The mask m can be found by







+ Eτ [fc(Φ(x0(· − τ),m))].
(2)
The first two terms of the loss function are used to introduce constrains on the perturbation
mask, in particular the second avoids finding adversarial examples. Since the model was
written in PyTorch using a Fast.ai wrapper we used its autograd package to obtain the
output derivative information with respect to a 15×15 pixels up-scaled perturbation mask.
Once the derivative information is obtained the mask can be found by using a gradient
descent approach to minimize the loss function defined above. Examples of perturbation
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Table C.3: Metric values of predicting Alzheimer’s disease and Diabetric retinopathy, statified
across groups. Groups were defined as dataset, age categories (in years), and gender. Given
are number of samples (#), absolute metric values of false negative rate (FNR), false omission
rate (FOR), negative predicted value (NPV), precision and predicted prevalence (PPREV)
with 95% confidence intervals (CI) and respective disparities to the reference as δ. Disparities
of 1.00 mark the reference group.
Diabetic Retinopathy
# FNR (CI) FNR δ FOR (CI) FOR δ NPV (CI) NPV δ precision (CI) prec. δ PPREV (CI) PPREV δ
diab dur: 0 538 0.10 (0.07-0.12) 1.00 0.10 (0.07-0.12) 1.00 0.91 (0.88-0.93) 1.00 0.91 (0.88-0.93) 1.00 0.49 (0.45-0.54) 1.00
diab dur: 1-10 170 0.18 (0.12-0.23) 1.79 0.09 (0.05-0.14) 0.96 0.91 (0.87-0.95) 1.00 0.77 (0.71-0.83) 0.85 0.36 (0.29-0.43) 0.73
diab dur: 11-19 97 0.07 (0.02-0.12) 0.70 0.20 (0.12-0.28) 2.10 0.80 (0.72-0.88) 0.88 0.94 (0.90-0.99) 1.04 0.74 (0.66-0.83) 1.51
diab dur: 20-29 37 0.22 (0.08-0.35) 2.22 0.26 (0.12-0.41) 2.76 0.74 (0.6-0.88) 0.81 1.00 (1.00-1.00) 1.10 0.49 (0.33-0.65) 0.99
diab dur: 30+ 6 0.00 (0.00-0.00) 0.00 0.00 (0.00-0.00) 0.00 1.00 (1.00-1.00) 1.11 1.00 (1.00-1.00) 1.10 0.83 (0.54-1.0) 1.69
age cat: 10-19 5 0.00 (0.00-0.00) NA 0.00 (0.00-0.00) 0.00 1.00 (1.00-1.00) 1.09 0.00 (0.00-0.00) 0.00 0.20 (0.00-0.55) 0.39
age cat: 20-29 17 0.00 (0.00-0.00) 0.00 0.00 (0.00-0.00) 0.00 1.00 (1.00-1.00) 1.09 0.57 (0.34-0.81) 0.62 0.41 (0.18-0.65) 0.80
age cat: 30-39 58 0.09 (0.02-0.17) 1.16 0.02 (0.00-0.06) 0.28 0.98 (0.94-1.00) 1.07 0.67 (0.55-0.79) 0.72 0.26 (0.15-0.37) 0.50
age cat: 40-49 191 0.12 (0.07-0.17) 1.53 0.11 (0.07-0.16) 1.33 0.89 (0.84-0.93) 0.97 0.88 (0.83-0.93) 0.96 0.48 (0.41-0.55) 0.93
age cat: 50-59 322 0.08 (0.05-0.11) 1.00 0.08 (0.05-0.11) 1.00 0.92 (0.89-0.95) 1.00 0.92 (0.89-0.95) 1.00 0.52 (0.46-0.57) 1.00
age cat: 60-69 181 0.13 (0.08-0.18) 1.66 0.17 (0.12-0.23) 2.05 0.83 (0.77-0.88) 0.90 0.95 (0.92-0.98) 1.03 0.55 (0.47-0.62) 1.06
age cat: 70+ 36 0.17 (0.05-0.30) 2.22 0.29 (0.14-0.43) 3.43 0.71 (0.57-0.86) 0.78 0.86 (0.75-0.98) 0.94 0.61 (0.45-0.77) 1.19
age cat: unknown 38 0.15 (0.04-0.26) 1.92 0.16 (0.04-0.27) 1.89 0.84 (0.73-0.96) 0.92 0.90 (0.80-0.99) 0.97 0.50 (0.34-0.66) 0.97
female 336 0.09 (0.06-0.12) 0.70 0.07 (0.04-0.10) 0.52 0.93 (0.90-0.96) 1.08 0.92 (0.89-0.95) 1.04 0.45 (0.40-0.50) 0.85
male 512 0.12 (0.09-0.15) 1.00 0.14 (0.11-0.17) 1.00 0.86 (0.83-0.89) 1.00 0.89 (0.86-0.91) 1.00 0.53 (0.48-0.57) 1.00
Alzheimer’s Disease
dataset: adni 129 0.15 (0.09-0.22) 1.00 0.15 (0.08-0.21) 1.00 0.86 (0.79-0.92) 1.00 0.75 (0.67-0.82) 1.00 0.52 (0.43-0.61) 1.00
dataset: edsd 67 0.31 (0.20-0.42) 2.05 0.23 (0.13-0.33) 1.60 0.77 (0.67-0.87) 0.90 0.91 (0.85-0.98) 1.23 0.36 (0.24-0.47) 0.69
age cat: 50-59 7 0.50 (0.13-0.87) 2.33 0.4 (0.04-0.76) 2.71 0.60 (0.24-0.96) 0.70 1.00 (1.00-1.00) 1.42 0.29 (0.00-0.62) 0.66
age cat: 60-69 39 0.15 (0.04-0.26) 0.70 0.15 (0.04-0.26) 1.02 0.85 (0.74-0.96) 1.00 0.90 (0.80-0.99) 1.27 0.49 (0.33-0.64) 1.12
age cat: 70-79 108 0.21 (0.14-0.29) 1.00 0.15 (0.08-0.21) 1.00 0.85 (0.79-0.92) 1.00 0.70 (0.62-0.79) 1.00 0.44 (0.34-0.53) 1.00
age cat: 80+ 42 0.20 (0.08-0.32) 0.93 0.26 (0.13-0.40) 1.78 0.74 (0.60-0.87) 0.86 0.87 (0.77-0.97) 1.24 0.55 (0.40-0.70) 1.26
female 99 0.18 (0.10-0.26) 1.00 0.18 (0.11-0.26) 1.00 0.81 (0.74-0.89) 1.00 0.82 (0.74-0.90) 1.00 0.51 (0.41-0.60) 1.00
male 97 0.24 (0.16-0.33) 1.36 0.18 (0.10-0.26) 0.97 0.82 (0.75-0.90) 1.01 0.76 (0.67-0.84) 0.92 0.42 (0.32-0.52) 0.84
masks are shown in Figure C.9. These masks are characterised by a high degree of noise
which was also observed using other interpretability techniques such as Saliency maps and
SHAP. Because of this noise it was not possible to find any useful clustering approach.
C.3.2. Diagnostic prediction of AD
The SHAP method was implemented using TreeSHAP, an implementation of the method
designed to efficiently calculate a local additive explanation for tree based models. We used
the tree path dependent option, which does not require any fitting on the training set. The
method generates an additive explanation in the following form






Where g is the local explanation, z is a vector containing binary values corresponding to
the presence of simplified explanation variables and φj is the attribution to each of these
variables. The explanations generated by SHAP have been combined with anchors, which
are local rules that “anchor” the prediction to its output value (i.e. the features that should
not be changed to keep the prediction the same). The definition of an anchor A is the
following
EDx(z|A)[1f(x)=f(z)] ≤ τ,A(x) = 1. (4)
Where D(z|A) is the distribution of neighbours which follow the anchoring rule A. Anchors
and SHAP values can provide the model owner with complementary information. SHAP
values, for example, can quantify the effect of a feature on the prediction but do not provide
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Figure C.9: Perturbation masks generated using the Meaningful Perturbation approach.
Pictures show the degree of noise characterizing these explanation masks and the different
rotations occurring in the original images.
information about local dependencies, which can be understood by using anchoring rules.
We generated anchors using the method implemented in the original paper, by specifying a
maximum rule length equal to 6 and a precision threshold of 95%. The selection of the most
representative explanations was done by first grouping the assessment sets according to their
position in the confusion matrix and to the subgroups identified during the bias analysis.
Once each subset of points was defined we applied a DBSCAN clustering algorithm using a
cosine similarity metric and a cluster radius of ε = 0.3. Figures C.10,C.11 and C.12 show
302
ML4H Auditing: From Paper to Practice
Figure C.10: Representative SHAP explanation for a False Negative prediction in the 50-59
age group. Corresponding anchoring rule is:
IF (rightententorhinalarea > 1.62) & (leftententorhinalarea > 1.59) & (rightacgganteriorcin-
gulategyrus <= 3.83) THEN PREDICTION IS FALSE
Figure C.11: Representative SHAP explanation for a False Negative prediction in the 60-69
age group. Corresponding anchoring rule is:
IF (rightententorhinalarea) > 1.46 & (leftententorhinalarea > 1.35) & (leftphgparahippocam-
palgyrus <= 2.73) & (rightthalamusproper <= 6.52) THEN PREDICTION IS FALSE
the SHAP force plots for the most representative false negatives subdivide according to their
age group.
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Figure C.12: Representative SHAP explanation for a False Negative prediction in the 60-69
age group. Corresponding anchoring rule is:
IF (rightententorhinalarea) > 1.72 & (leftententorhinalarea > 1.69) & (righthippocampus
<= 3.22) THEN PREDICTION IS FALSE
C.3.3. Cytomorphologic classification to aid leukemia diagnostics
The explanations for this model were generated using the Grad-CAM method. Grad-CAM
produces a coarse localization map to highlight region importance for a given activation
target based on the last convolutional layer of a CNN. We implemented it by using the
the keras-vis library. The clustering on the assessment set has been performed by first
grouping images based on their position in the confusion matrix then by clustering each
group according to their softmax outputs. We performed the clustering using DBSCAN
with a cosine similarity metric and an ε = 0.05.
C.4. Robustness assessment
In the context of machine learning for medical diagnosis we aim for a model f that is robust
with respect to (random) variations, naturally occurring during data acquisition. These
natural variations ought to be defined for medical data. For classical image recognition a set
of corruption functions C and a set of perturbation functions E is provided in Hendrycks
and Dietterich (2019), to define corruption robustness as the expected probability that
f(c(x)) = y holds true for label y and corruption c, whereas perturbation robustness is
defined as the expected probability that f(ε(x)) = f(x) holds true for the perturbation ε.
Since neither C nor E represent typical variations occurring in medical data we use the
corruption functions in C to analyse both: corruption robustness and perturbation robustness.
Moreover, we use the term perturbation to describe these two modes of robustness. The key
aspect of this analysis is not the specific choice of perturbation methods, but to describe a
general procedure after perturbation methods are fixed (potentially by some domain experts).
With this in mind we apply in a first step different perturbations with three severity levels
304
ML4H Auditing: From Paper to Practice
to our model, record the perturbed model output and compare it to the clean model output
in three different ways: visualize the (approximated) distribution density of the probability
scores of the correct classified points. Visualize the (approximated) distribution density of the
probability scores of the incorrect classified points. Visualize the (approximated) distribution
density of all probability scores. In a second step we measure the effect of these perturbations
by the mean corruption error (mCE) proposed in Hendrycks and Dietterich (2019). This is
an empirical metric, unlike more theoretical approaches to calculate robustness bounds as
the Lipschitz constant (Szegedy et al., 2013), which can be too loose or hard to calculate for
complex models. In Hendrycks and Dietterich (2019) the mean corruption error is calculated
as follows: For a trained classifier f calculate the top-1 error rate for each perturbation type
c, with a varying level of severity s, written as Efs,c. The model’s error rate tested with the
unperturbed observations is defined as Efclean. Authors in Hendrycks and Dietterich (2019)
recommend a normalization using a baseline to account for the different degrees of difficulty.
In this work, as we test one completely black box model with access only to test data, we
normalize it against the error rate of the tested model with the perturbations and define the














The mean corruption error mCE is calculated by averaging over the corruption errors.
C.4.1. Diabetic Retinopathy model
The retinopathic detection problem is a classification problem based on unstructured data
input. These unstructured data are composed of images from the ophthalmology domain,
treated as a classical image pattern recognition problem. Unstructured data comes from
different scopes, which the quality of this can be very low. Also consider that there may be
disturbances that occur in daily life of the domain that can alter the decision of the model.
For this reason, IA engineers incorporate these corruptions into transformations in the
preprocessing data augmentation process in order to simulate these corruptions, to improve
the inference of the model. In this use case, the owner of the model, use in total seven
different types of transformations to augment the data set, the outlines transformations are
flip, rotate, zoom, contrast, brightness, lighting and sketch, without damaging the image
semantic domain. For this reason in this section we outline perturbation methods on image
data based on Hendrycks and Dietterich (2019) to evaluate the model robustness. For image
data we have a three channel images (red, green, blue). The model input consists of this
color images.
Perturbation of images We apply perturbation to images, where the feature space of the
normal images are from 0 to 255 in the three channels of color (RGB), we have to make sure
that this perturbed images are from the same color feature space. In the experiments we
apply in total 16 perturbations on four different background to the images using the functions
from the Github repository of Hendrycks and Dietterich (2019): brightness, contrast, elastic
transform, fog, frost, Gaussian blur, jpeg compression, pixelate, saturate, speckle noise,
spatter, Gaussian noise, shot noise, impulse noise, defocus blur and motion blur. For each
perturbation we apply three severity level: 0, 2, 4 on all 843 images in the test set spread
along all the classes, where the data was provided by the use case owner. On the first
experiment we expose the elastic transform perturbation to the input data C.13.
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Figure C.13: Perturbation: Elastic transform. For Diabetic Retinopathy model. The
densities of the probability scores of the perturbed model differ only slightly compared to
the clean versions, along all three plots.
Figure C.14: Noise corruptions. For Diabetic Retinopathy model. The densities of the
incorrect classified points included the non gradable class for each severity tends to shift
to higher values. The correct classified points shift to lower values or flatting thought the
noises.
We call the model robust regarding to the perturbed features with the three severity, we
can observe the model only predicts six wrong outputs for severity 0, setting the accuracy
to drop 1%. Has a lightly effect on the model output. For the experiments using noise
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Figure C.15: Weather corruptions. For Diabetic Retinopathy model. There are a few points
correct when the data is exposed to the weather corruptions where the incorrect classified
points shift highest values for incorrect predictions outputs. The use case owner addressed
that this kind of perturbations is unseen in ophthalmology domain.
perturbations as in figure C.14, the effect has an immense impact on the model outputs
predictions, setting the model to behave insecure and classified the outputs as a non gradable
(image quality not sufficient for diagnosis), in this kind of situation we record this outputs
into incorrect classified point, consider that the image quality may produced wrong prediction
outputs of the model even for an expert in this domain field. Some of the corruptions exposed,
there are some perturbations that are atypical in the ophthalmology domain, the use case
owner listed some of them: fog, frost addressed in the figure C.15, high level of contrast and
brightness, Jpeg compression in the figure C.16 can damage the semantic domain of the
data, where not even an expert of this domain has a good diagnosis of the image. For some
corruptions of noise, the effect can be reproduce of the dust in the camera where is taken
the image for diagnosis as can see it on the figure C.14, also for the blur corruption cause by
the unfocused or the movement of the camera when the picture is taking, the results are
addressed in the figure C.17. We also labeled some extra corruption function to evaluate the
model robustness, we condensed this results in figure C.18.
Mean corruption error The metric to evaluate the diabetic retinopathy model robustness
is defined in formula 5. We apply in total 16 perturbation functions for severity s ∈ {0, 2, 4}
with Efclean = 0.2232 and record the results of the experiment in ascending order in 1. The
mean corruption error along all perturbations is mCE = 0.6336.
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Figure C.16: Digital corruptions. For Diabetic Retinopathy model. Some digital corruptions
are possible in ophthalmology domain, the image compression, quality. For example the
pixelate and jpeg compression, where the pixelate corruption have a small impact in the
model decision against the jpeg compression. The jpeg compression have a strong effect on
the model decision outputs where the correct classified points tends to sketch to the left or
right side.
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Figure C.17: Blur corruptions. For Diabetic Retinopathy model. The bur corruption has
strong influence on the model correct classified points, the distribution density flatter to
lower values for each severity levels.
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Figure C.18: Extra corruptions. For Diabetic Retinopathy model. These corruptions have a
strong influence, sketching the correct classified points distribution density values to lower
values. In the other hand the incorrect classified points are flatter in the space. We might
call the model not robust against this extra perturbations, where the correct classified points
start to drop.
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C.4.2. AD model
In contrast to the Diabetic Retinopathy model and the cytomorphology model, the input for
the AD model is structured data. Since this structured data is extracted from MR-images,
the perturbations should be applied directly to these images rather than to the extracted
features. Nevertheless, test engineers do not always have access to these images. For that
reason we outline in this section perturbation methods for tabular data based on Eduardo
et al. (2019). For tabular data we distinguish between categorical features (that can only
take a finite number of values) and continuous features (that can take uncountable many
values). The AD model input consists of fifteen continuous features: age and fourteen brain
features and one categorical feature: gender.
Perturbations of continuous features If we apply perturbations to images, we need to
ensure that the perturbed pixels are still in the used color range. With continuous features
in tabular data we face the same problem, but in general, we do not know the ranges of
the features. To ensure that the perturbed data is still in the feature space, we choose the
range for each feature according to the maximum and minimum value of this feature in the
test set. Assuming continuity, we ensure that the perturbed features end up in the feature
space, by cutting of higher and lower values after sampling. We apply three different types
of noise to the continuous features: Gaussian noise (Gn), Laplace noise (Ln) and log-normal
noise (lln) with three different severity levels. In order to determine the variance of these
distributions, we calculate the standard deviation σ̂k of feature k in the test set and define
the variance as σk := s · σ̂k with respect to some scaling s. Figure C.19 shows the effect of
the continuous perturbation, applied to all brain features.
Perturbations of the categorical feature gender There is only one categorical feature
in the model: gender. The authors in Eduardo et al. (2019) propose the following perturbation
method for categorical features: Replace the categorical feature of data point x by a discrete







with scaling factor β ∈ [0, 1], where pc is the relative frequency of the value c
in the test set. Note that for β = 0 we sample from a uniform distribution and for β = 1
we sample according to the relative frequency. So β can be seen as a scaling factor on how
much we take the relative frequency into account. Further, the authors propose to leave out
the true value of the feature in x, so that each categorical feature is perturbed. In our case
this approach leads to a deterministic perturbation, where we replace each gender by its
counterpart. We define the first categorical perturbation for the feature gender according
to the approach above, but consider the true value of each feature as well during sampling.
The effect of this perturbation is shown in figure C.20.
In the second perturbation method we first assign male to each feature, second assign
female to each feature and third replace each gender by its counterpart.The effect of this
perturbation is visualized in figure C.21.
For both categorical perturbations, the perturbed model differs very mildly in prediction
and in overall model output from the clean model. This observation holds among all applied
severity levels. For that reason we might call the AD model robust with respect to the
feature gender.
Mean corruption error To quantify the effect of the perturbations we calculate the
mean corruption error over all eight perturbations: the three continuous perturbations
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Figure C.19: The distribution densities of the probability scores flatten throughout all noise
types. The scores of the correct classified points shift to lower values. For Gaussian noise
and Laplace noise of scale 0.2 we might call the model robust, since accuracy changes only
by one point. For all other noise types and scaling levels, we observe a decrease of accuracy
at least by 9%. The perturbation of lognormal noise with s ∈ {1, 2} diminishes the accuracy
of the model close to random guessing and worse.
specified above, applied to age and brain features with s ∈ {0.2, 0.5, 1} for Gn and Ln and
s ∈ {1, 2, 8} for lln. The categorical perturbation with β ∈ {0, 0.5, 0.8} and the deterministic
perturbation. The corruption errors of these perturbations calculated according to (5)
are listed in C.4 in ascending order. The mean corruption error differs (slightly) from
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Figure C.20: The effect of the categorical perturbation is slightly visible in the distribution
densities of the probability scores. The perturbed prediction differs at most by three points
from the clean prediction.
Figure C.21: Setting the gender for all medical representatives first to male and second to
female leads only to a decrease of incorrect classified points by two and three. Replacing the
gender by its counterpart leads to four more incorrect classified points.
trial to trial due to the stochasticity of the perturbations. The calculations in C.4 can be
reproduced with the plots and statistics provided in the folder AD robustness analysis at
https://github.com/luisoala/daisam. Averaging over all these errors leads to a mean
corruption error of mCE = 0.1766.









s,c − Efclean CE
f
c
Gn on age 0.5765 -0.0051 -0.0088
Ln on age 0.5816 1.1E-16 1.9E-16
lln on age 0.6020 0.0204 0.0339
categorical perturbation 0.6071 0.0255 0.0420
deterministic perturbation 0.6224 0.0408 0.0656
Gn on brain features 0.9031 0.3214 0.3559
Ln on brain features 0.9031 0.3214 0.3559
lln on brain features 1.3469 0.7653 0.5682
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C.4.3. Cytomorphology model
To run the robustness experiments a ResNeXt model was provided by the use case owner,
details on the training process are explained extensively in Matek et al. (2019). The model
was used to classify RGB images of size 400 × 400 into 15 different classes. The test set
consisted of 73 images distributed along all the classes, the data was provided by the use
case owner.
Image perturbation The perturbations applied to this model test set, where the ones
proposed by Hendrycks and Dietterich (2019), the images on the test set where RGBA images
so in order to apply the perturbations and the inference, the alpha channel was ignored for
the perturbation process and also the inference. To simplify the analysis, three perturbation
severity levels where used, 0, 2 and 4. Variation on the effect of the perturbations, exposed
the need of feedback from the use case owner in order to select transformations that modeled
real case scenarios to which the model should be robust to, this led to ignore the results of
the contrast, fog, frost, motion blur and saturate perturbations.
Digital transformations like pixelation, jpeg compression and different brightness levels
were selected as the most plausible perturbations, for the pixelation and jpeg compression
the model accuracy and softmax output values were very similar as seen in C.22, but the
brightness perturbation produced a spike on the incorrect classifications and its confidence.
This shows that the model is susceptible to variations in the brightness of the images and
this kind of perturbation may produce overconfident results.
Mean corruption error To calculate the metric, all 16 perturbations were evaluated on
its three degrees of severity, the results are presented in table C.5.









s,c − Efclean CE
f
c
Elastic transform 0,7671 -0,0548 -0,0714
Pixelate 0,8630 0,0411 0,0476
JPEG compression 0,9315 0,1096 0,1176
Motion blur 1,1507 0,3288 0,2857
Defocus blur 1,1781 0,3562 0,3023
Gaussian blur 1,2055 0,3836 0,3182
Spatter 2,1233 1,3014 0,6129
Gaussian noise 2,1918 1,3699 0,6250
Frost 2,4110 1,5890 0,6591
Speckle noise 2,5068 1,6849 0,6721
Shot noise 2,534 1,7123 0,6757
Impulse noise 2,5342 1,7123 0,6757
Brightness 2,6712 1,8493 0,6923
Contrast 2,6986 1,8767 0,6954
Saturate 2,7808 1,9589 0,7044
Fog 2,8767 2,0548 0,7143
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Correct model output predictions
approximated density - 53 correct classifications
severity 0 - 52 correct classifications
severity 2 - 52 correct classifications
severity 4 - 52 correct classifications

















Incorrect model output predictions
approximated density - 20 incorrect classifications
severity 0 - 21 incorrect classifications
severity 2 - 21 incorrect classifications
severity 4 - 21 incorrect classifications























Pixelate perturbation for each severity




















Correct model output predictions
approximated density - 53 correct classifications
severity 0 - 50 correct classifications
severity 2 - 50 correct classifications
severity 4 - 51 correct classifications



















Incorrect model output predictions
approximated density - 20 incorrect classifications
severity 0 - 23 incorrect classifications
severity 2 - 23 incorrect classifications
severity 4 - 22 incorrect classifications
























Jpeg compression perturbation for each severity




















Correct model output predictions
approximated density - 53 correct classifications
severity 0 - 8 correct classifications
severity 2 - 8 correct classifications
severity 4 - 8 correct classifications




















Incorrect model output predictions
approximated density - 20 incorrect classifications
severity 0 - 65 incorrect classifications
severity 2 - 65 incorrect classifications
severity 4 - 65 incorrect classifications

























Brightness perturbation for each severity
Figure C.22: Digital corruptions on the cytomorphology dataset.
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Appendix D. FG-AI4H Overview
The FG-AI4H ”works in partnership with the World Health Organization (WHO) to
establish a standardized assessment framework for the evaluation of AI-based methods
for health, diagnosis, triage or treatment decisions” according to the initiative’s website.
To that end FG-AI4H has produced reference documentation for the assessment process
which is summarized in Figure 1 of the main paper. In the following, we provide short
summaries of what each of these documents aims to achieve. The full documents can be
accessed via the ITU collaboration environment at https://extranet.itu.int/sites/
itu-t/focusgroups/ai4h/SitePages/Home.aspx3.
D.1. ITU/WHO FG-AI4H reference documents
AI4H ethics considerations (DEL 01) This document discusses the ethical issues and
challenges posed by digital technologies including AI/ML technologies and tries to provide
harmonised ethics guidance for the design and implementation of AI in global health especially
for the benefit of how low- and middle-income countries.
Good practices for health applications of machine learning: Considerations
for manufacturers and regulators (DEL 2.2) This document presents a set of good
machine learning practice guidelines intended to educate the developers and manufacturers
of healthcare AI solutions on conducting a comprehensive requirements analysis and stream-
lining conformity assessment procedures for continual product improvement in an iterative
and adaptive manner in conformance to the appropriate standards and regulations.
Data requirements (DEL 5.1) This document presents the acceptance criteria for data
submitted to the FG-AI4H and states the governing principles and rules. These principles
are crucial because the core of the benchmarking framework for AI for health methods will
be an undisclosed test data set – per use case of each topic area to be defined – that will not
be made accessible to the AI developers. combines a set of four deliverables as umbrella.
Data acquisition (DEL 5.2) This document presents a framework for public healthcare
data acquisition and management model based on standard protocol for its easy adoption
by any country or international health organizations.
Data annotation specification (DEL 5.3) This document provides general guideline
of data annotation specification, including definition, background and goals, framework,
standard operating procedure, scenario classifications and corresponding criteria, as well as
recommended metadata, etc.
Training and test data specification (DEL 5.4) This document provides guidelines
on the systematic way of preparing technical requirements specification for datasets used in
training and testing of ML models and discusses the best practices of data quality assurance
aimed at minimizing the data error risks during the training and test data preparation phase
of machine learning process lifecycle.
Data handling (DEL 5.5) This document provides information on the data handling
policies, the need for a factual framework in compliance with data protection laws and
regulations dealing with the use of personal health data. It also outlines how data will be
handled, once they are accepted.
3. An ITU user account is necessary for access which we obtained free of charge like so https://www.itu.
int/en/ITU-T/focusgroups/ai4h/Documents/registrationsteps.pdf
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Data sharing (DEL 5.6) This document outlines the established data sharing methods
and novel methods based on distributed and federated environments for privacy preserving
AI/ML models. The scope of this document includes a description of all the necessary steps
and requirements to enable secure data sharing and the specifications of the role of the data
providers, data processors and the data receivers.
Topic Description Document(TDD) (DEL 10) This document specifies the require-
ments of a standardized benchmarking process for the specific AI-based use case of the
respective Topic Group within the AI4H Focus Group. It covers all scientific, technical, and
administrative aspects relevant for setting up this benchmarking.
Data and artificial intelligence assessment methods (DAISAM) reference
(DEL 7.3) This document provides a comprehensive overview and discusses in detail,
the data and ML model quality assessment methods for evaluating the bias, interpretability,
and robustness for different use cases represented by the Topic Groups.
Clinical evaluation of AI for health (DEL 7.4) The document provides guidelines
for the evaluation of AI in health for use by researchers, clinicians/patients, developers, and
policy makers with a framework to understand whether the models are safe, effective and
cost- effective, and also to compare model performance with current standards of care, and
between each other to facilitate clinically meaningful improvements in a complex clinical
environment.
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